EP2370053A1

EP2370053A1 - Novel powdered crystalline medicines for inhalation

Info

Publication number: EP2370053A1
Application number: EP09756312A
Authority: EP
Inventors: Claudius Weiler; Marc Egen
Original assignee: Boehringer Ingelheim International GmbH
Current assignee: Boehringer Ingelheim International GmbH
Priority date: 2008-11-27
Filing date: 2009-11-23
Publication date: 2011-10-05
Also published as: US20150258030A1; WO2010060875A1; US20120135969A1; CA2744655A1; JP2012509922A

Abstract

The invention relates to a manufacturing method for preparing inhalation powders and to stable and crystalline inhalation powders manufactured using said method. The invention also relates to the use of said inhalation powder for preparing a medicine for treatment of respiratory tract illnesses, in particular for treating COPD (chronic obstructive pulmonary disease) and asthma.

Description

NEW POWDER-MOLDED CRYSTALLINE DRUGS FOR INHALATION

The invention relates to stable pharmaceutical compositions for inhalation use, wherein one or more active ingredients are embedded in a crystalline matrix of an excipient. In particular, the invention relates to spray-dried, crystalline and storage-stable powders wherein one or more active ingredients are embedded in a crystalline mannitol matrix. Furthermore, the invention relates to processes for their preparation and the use for the production of a medicament for the treatment of Atemwegserkrnakungen, in particular for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

BACKGROUND OF THE INVENTION In the case of the powder inhalant application form, inhalable powders which are filled, for example, into suitable capsules (inhalettes) are applied by means of powder inhalers in the lungs. Also known are other systems in which the amount of powder to be applied is pre-dosed (e.g., blisters) as well as multi-dose powder systems. Alternatively, an inhalative application can also be carried out by application of suitable powdered inhalation aerosols, which are suspended, for example, in HFAI 34a, HFA227 or their mixture as propellant gas.

In powder inhalation, the microparticles of a pure drug are transported through the airways on the lung surface, e.g. in the alveoli, by means of the inhalation process applied. These particles sediment on the surface and can be absorbed by the active and passive transport processes in the body only after the dissolution process.

Known in the literature are inhalation systems in which the active ingredient is present in the form of solid particles either as a micronized suspension in a suitable solvent system as carrier or in the form of a dry powder. Usually, powder inhalants, for example in the form of capsules for inhalation, based on the general teaching, as described in DE-A-179 22 07, prepared. A critical factor in such multi-component systems is a uniform distribution of the drug in the powder mixture. Another important aspect of powder inhalation is that only particles of a certain aerodynamic size reach the target organ lung during the inhalative application of the active ingredient. The average particle size of these respirable particles (inhalable fraction) is in the range of a few micrometers, typically between 0.1 and 10 .mu.m, preferably below 6 .mu.m. Such particles are usually produced by micronization (air jet milling). As a result, it often happens that such particles can be complex in their crystal properties due to this mechanical step.

It is known from the literature that particles in the range of less than 10 μm can be produced by means of spray drying. The spray-drying of pure active ingredients for inhalation purposes (powder inhalation) has also been described in the prior art [for example: EP 0 072 046 A1; WO 2000 000176 A1; US 6019968; A. Chawla, K.M.G. Taylor, J.M. Newton, M.C.R. Johnson, Int. J. Pharm, 108 (3), (1994), 233-240]. Especially in the field of pulmonary therapy, spray-drying is a suitable method for preparing peptide / protein-containing powders for the treatment of various diseases [US Pat. No. 5,626,874; US 5,972,388]

Formulation systems are known to the person skilled in the art, wherein co-spray micronisates of active substances and physiologically acceptable auxiliaries [WO 9952506] are disclosed for inhalative administration. Also known are powder preparations comprising co-spray micronisates of SLPI protein in physiologically acceptable carrier materials [WO 99/170000]; Co-spray-dried interferon with a carrier material [WO 9531479] and co-spray micronisates of an active ingredient and cellulose derivatives [WO 9325198].

The specific use of mannitol as an assistant for co-spray micronisates for the stabilization of peptides and proteins is described in WO 05/020953. Disclosed herein are formulations characterized by having complex proteins in an amorphous matrix in the form of embedment particles characterized by good long-term stability and inhalability.

Conventional inhalable spray-drying formulations and their preparation processes are thus based on the concept that the amorphous or glassy state obtained primarily by spray-drying is stabilized and for the purpose of long-term stability is maintained. The property of long-term stability in the sense of the invention can be simulated by stress storage. In this case, storage according to the conditions "40 ° C. at 75% relative humidity, stored open for one week" may be used as a characteristic to assess that an inhalative formulation is considered to be long-term stable

05/020953, serve to reduce the proportion of water in order to stabilize the amorphous state of these spray-drying formulations, which may be accompanied by an uncontrolled crystallization.

The object of the invention is to provide crystalline particles for inhalation application, wherein at least one pharmaceutically active substance is embedded in a crystalline matrix of an excipient.

A further object of the invention is to utilize the stabilizing effect of the crystalline state for spray-dried inhalable embedding particles.

A basic object of the invention is to provide spray-dried powders which are distinguished by good long-term stability and inhalability. The decisive factor here is a balanced balance between both criteria.

The object of the invention is also to provide a manufacturing method for providing the inhalable powder according to the invention.

Another object of the present invention is pharmaceutical preparations for inhalation application, be it in the form of a dry powder, a propellant-containing metered dose inhaler or a propellant-free inhalable solution.

Summary of the invention

Surprisingly, it has been found that the methods mentioned in the prior art are not suitable for providing inhalable powders which comprise one or more active pharmaceutical ingredients and a matrix former, the Matrix former present in crystalline form. The powders are characterized by a high stability.

For the purposes of the present invention, stable inhalable powders are to be understood as meaning inhalable powders whose properties remain unchanged over a relatively long period of time. Inhalation powders will not change their properties if both the chemical stability of the individual components in the powder mixture and their physical or physicochemical stability is given. This also assumes that the components of the powder mixture remain unchanged in terms of their polymorphic and morphological properties. For inhalation powder physical stability plays a prominent role.

In a preferred embodiment, the powder consists predominantly of finely divided inhalable particles having an average aerodynamic particle size (MMAD) of <10 .mu.m, preferably 0.5-7.5 .mu.m, more preferably 1-5 .mu.m. The matrix formers here can be sugars, polyols, polymers or a combination of these. Preference is given here to polyols, wherein the mannitol plays a prominent role.

Powders of the invention are characterized in that they have a high inhalable content. The Fine Particle Dose represents the amount of inhalable active substance particles (<5 μm), as described on the basis of Pharm. Eur. 2.9.18 (European Pharmacopoeia, 6th edition 2008, Apparatus D - Andersen Cascade Impactor) or USP30-NF25 < 601> is determinable. In the context of the present invention, the inhalable particles as

This is understood to mean the proportion of the inhalable powder whose particles are smaller than 5 μm, measured by laser diffraction (stated in [%]) an inhaler (Handihaler).

The powders according to the invention are formulations of pharmaceutical products, predominantly for inhalative applications, which contain one of the powders according to the invention described herein. In this connection, the invention also encompasses pharmaceutical compositions which contain the powders according to the invention as propellant-containing metered-dose aerosols or as propellant-free inhalable solutions. The invention further provides a process consisting of spray-drying and an additional, integrated second drying zone for preparing preparations of crystalline spray-drying particles. With the help of this second drying zone, first a removal of the solvent and then a crystallization of the matrix-forming agent in the spray tower. By a second drying step, the complete drying of the crystallized particles takes place before a deposition takes place in the collecting vessel of the spray dryer.

The temperature for the spray-drying process is below 135 ° C

(Einströmtemperatur), preferably below 105 ⁰ C of the drying gas 1. As the second drying stage ambient air is sucked and fed to the process (drying gas 2), the temperature of which is between 300 ⁰ C and 400 ⁰ C and the ratio of drying gas 1 to drying gas between 20 to 1 and 3 to 1. The resulting initial temperature is in the range of about 50 ⁰ C to 70 ⁰ C.

The present invention provides spray-dried crystalline powders having improved properties in terms of their properties, such as flowability, dispersibility, and storage and process stability. The present invention is characterized by high constancy of the application of the active substance with varied flow. The present invention thus solves problems which have arisen in the previous formulation development, in particular in the use of mannitol-containing spray-drying powders, since their insufficient crystallinity had a negative influence on the physical and chemical stability of the powders.

Detailed description of the invention

By means of the method according to the invention for the preparation of an inhalation powder for pulmonary (or nasal) inhalation, the active ingredient (or a physiologically acceptable salt thereof) is physically stably incorporated as a solid in a crystalline solid matrix of an adjuvant.

By appropriate selection of excipients, the active ingredient can be incorporated into the solid matrix with the method according to the invention in such a way that this excipient serves as a matrix former and thus improves the physical stability of the spray-dried particles. Surprisingly, it was found that the solve the aforementioned objects by the crystalline matrix particles prepared by the process according to the invention.

In principle, matrix formers can be sugars, polyols, polymers, amino acids, di-, tri-, oligo-, polypeptides, proteins, or also salts. Examples of particularly suitable sugars here are raffinose and galactose. Examples of particularly suitable sugar alcohols include mannitol, xylitol, maltitol, galactitol, arabinitol, adonitol, lactitol, sorbitol (glucitol), pyranosylsorbitol, inositol, myoinositol and meso-erythritol , Mannitol, xylitol, maltitol and sorbitol may be mentioned as preferred. As examples of particularly suitable amino acids, leucine, lysine and glycine may preferably be called leucine. According to the invention prove to be matrix sugar as well as their corresponding alcohols to be advantageous to have a Tg of less than 40 ⁰ C. The mannitol plays an outstanding role here. The Tg of a powder can be determined experimentally by means of DSC (DSC = Differential Scanning Calorimetry) (Breen et al, 2001, Pharm. Res., 18 (9), 1345-1353). Here, the increase of the heat capacity is recorded as a function of the temperature.

A solid is called crystalline if its smallest parts are regularly arranged. The opposite is amorphous. Methods for determining crystallinity are DSC, density measurement, X-ray diffraction, IR spectroscopy or NMR. For the purposes of the present invention, crystalline is understood as meaning when the pulverulent formulations have a crystallinity of at least 90%, preferably at least 92.5% and in particular at least 95%. Likewise particularly preferred are a crystallinity of at least 96%, of at least 97%, of at least 98%, and of at least 99%. The crystallinity in the sense of the present invention can be determined here in accordance with the information in the section "Methods".

Inhalable powders which are provided according to the preparation process according to the invention contain a pharmaceutical active substance. In an independent embodiment, the inhalable powders which are provided according to the preparation process according to the invention contain a combination of 2 or 3 active pharmaceutical ingredients. A "pharmaceutically active substance is to be understood as meaning a substance, a medicament, a composition or a combination thereof which has a pharmacological, mostly positive, effect on an organism, an organ, and / or a cell, if the active substance interacts with the organism, organ or the cell is brought into contact. Incorporated into a patient, the effect can be local or systemic.

The chemical compounds (active substances) listed below can be used alone or in combination as a drug-relevant constituent of the inhalable powders according to the invention.

In the compounds listed below, W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, PAF - Antagonists and PB kinase inhibitors. Furthermore, two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W would be:

W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,

W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists, W represents a corticosteroid combined with a PDE4 inhibitor, EGFR inhibitors or LTD4 antagonists - W represents a PDE4 Inhibitors combined with an EGFR inhibitor or LTD4 antagonist W represents an EGFR inhibitor combined with a LTD4 antagonist.

Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol , Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL-1248 and

3- (4- {6- [2-Hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethyl-amino] -hexyloxy} -butyl) -benzyl-sulfonamide

5- [2- (5,6-diethyl-indan-2-ylamino) -l-hydroxyethyl] -8-hydroxy-1H-quinolin-2-one 4-hydroxy-7- [2 - {[2- {[3- (2-phenylethoxy) propyl] sulphonyl} ethyl] amino} ethyl] -2 (3H) -benzothiazolone 1- (2-Fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol 1- [3- (4-methoxybenzylamino) -4-hydroxyphenyl] - 2- [4- (l-benzimidazolyl) -2-methyl-

2-butylamino] ethanol 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-N, N-dimethylaminophenyl) -2-methyl- 2-propylamino] ethanol 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-methoxyphenyl) -2-methyl-2-propylamino] ethanol 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-n-butyloxyphenyl) -2-methyl]

2-propylamino] ethanol - 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- {4- [3- (4-methoxyphenyl) -l, 2, 4-triazol-3-yl] -2-methyl-2-butylamino} ethanol

5-hydroxy-8- (1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazine-3- (4H) -on- (4-amino-3-chloro-5-trifluoromethylphenyl) -2-tert .-butylamino) ethanol

6-Hydroxy-8- {1-hydroxy-2- [2- (4-methoxyphenyl) -1,1-dimethylethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one

6-Hydroxy-8- {1-hydroxy-2- [2- (4-phenoxy-acetic acid ethyl ester) -l, 1-dimethyl-ethylamino] -ethyl} -4 H -benzo [1,4] oxazin-3-one

6-Hydroxy-8- {1-hydroxy-2- [2- (4-phenoxyacetic acid) -1,1-dimethylethylamino] ethyl} -4H-benzo [1,4] oxazin-3-one - 8- {2- [l, 1-dimethyl-2- (2,4,6-trimethylphenyl) -ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4-oxazine-3-] on

6-hydroxy-8- {1-hydroxy-2- [2- (4-hydroxyphenyl) -1,1-dimethyl-ethylamino] -ethyl} -

4H-benzo [l, 4] oxazin-3-one

6-Hydroxy-8- {1-hydroxy-2- [2- (4-isopropyl-phenyl) -l, 1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one

8- (2- [2- (4-ethylphenyl) -1,1-dimethylethylamino] -1-hydroxyethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3-one

8- (2- [2- (4-Ethoxy-phenyl) -1,1-dimethyl-ethylamino] -l-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4-oxazin-3-one] 4- (4- {2- [2-Hydroxy-2- (6-hydroxy-3-oxo-3,4-dihydro-2H-benzo [l, 4] oxazin-8-yl) ethylamino] -2- methyl-propyl} -phenoxy) -butyric acid

8- {2- [2- (3,4-difluorophenyl) -1,1-dimethylethylamino] -1-hydroxyethyl} -6-hydroxy

4H-benzo [l, 4] oxazin-3-one

1 - (4-ethoxycarbonylamino-3-cyano-5-fluorophenyl) -2- (tert -butylamino) ethanol 2-Hydroxy-5 - (1-hydroxy-2- {2- [4- (2-hydroxy-2-phenyl-ethylamino) -phenyl] -ethylamino} -ethyl) -benzaldehyde

N- [2-hydroxy-5- (1-hydroxy-2- {2- [4- (2-hydroxy-2-phenyl-ethylamino) -phenyl] -ethylamino} -ethyl) -phenyl] -formamide - 8- Hydroxy-5- (1-hydroxy-2- {2- [4- (6-methoxy-biphenyl-3-ylamino) -phenyl] -ethylamino} -ethyl) -1H-quinolin-2-one

8-Hydroxy-5 - [1-hydroxy-2- (6-phenethylamino-hexylamino) -ethyl] -1 H-quinolin-2-one

5- [2- (2- {4- [4- (2-Amino-2-methylpropoxy) -phenylamino] -phenyl} -ethylamino) -1-hydroxy-ethyl] -8-hydroxy-1H-quinoline -2-one - [3- (4- {6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -5-methylphenyl] -urea

4- (2- {6- [2- (2,6-dichloro-benzyloxy) -ethoxy] -hexylamino} -1-hydroxy-ethyl) -2-hydroxymethyl-phenol

3- (4- {6- [2-Hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) -ethylamino] -hexyloxy} -butyl) -benzylsulfonamide

3- (3- {7- [2-Hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) -ethylamino] -heptyloxy} -propyl) -benzylsulfonamide

4- (2- {6- [4- (3-Cyclopentanesulfonyl-phenyl) -butoxy] -hexylamino} -1-hydroxy-ethyl) -2-hydroxymethyl-phenol-N-adamantan-2-yl-2- (3 - (2- [2-hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) ethylamino] -propyl} -phenyl) -acetamide

optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,

Preferred anticholinergic compounds here are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts the chloride salt, tolterodine. In the As anions, the abovementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions. Of all the salts, the chlorides, bromides, iodides and methanesulfonates are particularly preferred.

Likewise preferred anticholinergics are selected from the salts of the formula AC-I

wherein X ^{~ is} a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-Toluenesulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates. Of particular importance are those drug combinations which contain the enantiomers of the formula AC-I-ene

contain, wherein X ^{~ can have} the meanings given above. Further preferred anticholinergics are selected from the salts of the formula AC-2 wherein R is either methyl or ethyl and in which X ^{~ may have} the abovementioned meanings. In an alternative embodiment, the compound of the formula AC-2 may also be present in the form of the free base AC-2-base.

Further named compounds are:

2,2-Diphenylpropionic acid-tropol ester-methobromide 2,2-diphenylpropionic acid copolester-methobromide - 2-fluoro-2,2-diphenylacetic acid-co-ester methobromide 2-fluoro-2,2-diphenylacetic acid-tropol ester-methobromide 3,3 ', 4,4'-tetrafluorobenzilic acid-tropol ester-methobromide 3,3 ', 4,4'-Tetrafluorobenzilic Acid Copoester Methobromide 4,4'-Difluorobenzilic Acid-Sterol Ester Methobromide - 4,4'-Difluorobenzilic Acid Copoprene Methobromide 3,3'-Difluorobenzilic Acid-Sterol Ester Methobromide 3,3'-Difluorobenzilic Acid Copoprene Ester Methobromide 9-Hydroxy fluorene-9-carboxylic acid tropol ester methobromide 9-fluoro-fluorene-9-carboxylic acid-tropol ester-methobromide - 9-hydroxy-fluorene-9-carboxylic acid-co-ester methobromide 9-fluoro-fluoren-9-carboxylic acid-co-ester methobromide 9-methyl-fluorene-9-carboxylic acid-tropol ester Methobromide 9-Methyl-fluorene-9-carboxylic acid copo-ester-methobromide B enzilsäurecy clopropy ltropinester-methobromide - 2,2-Diphenylpropionic acid cyclopropyltropine ester methobromide

9-hydroxy-xanthene-9-carbonsäurecyclopropyltropinester methobromide 9-methyl-fluorene-9-carbonsäurecyclopropyltropinester methobromide

9-methyl-xanthene-9-carbonsäurecyclopropyltropinester methobromide

9-hydroxy-fluorene-9-carbonsäurecyclopropyltropinester methobromide

Methyl 4,4'-difluorobenzilate cyclopropyltropine ester methobromide - 9-hydroxy-xanthene-9-carboxylic acid-tropol ester-methobromide

9-hydroxy-xanthene-9-carbonsäurescopinester methobromide

9-methyl-xanthene-9-carbonsäuretropenolester methobromide

9-methyl-xanthene-9-carbonsäurescopinester methobromide

9-Ethyl-xanthene-9-carboxylic acid-tropol ester-methobromide - 9-difluoromethyl-xanthene-9-carboxylic acid-tropol ester-methobromide

9-hydroxymethyl-xanthene-9-carboxylic acid-co-ester methobromide The abovementioned compounds can also be used in the context of the present invention as salts in which the salts Metho-X are used instead of the methobromide, where X is as defined above for X ^" may have.

Preferred corticosteroids here are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR - 106541, NS-126, ST-26 and

6,9-Difluoro-17 - [(2-furanylcarbonyl) oxy] -11-hydroxy-16-methyl-3-oxo-androsta-1, A-diene-17-carbothionic acid (S) -fluoromethyl ester

6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothionic acid (S) - (2-oxo-tetrahydrofuran-3 S-yl ) esters, - 6α, 9α-difluoro-1-l-hydroxy-16α-methyl-3-oxo-17α- (2,2,3,3-tertamethylcyclopropylcarbonyl) oxy-androsta-1,4-diene-17β- carboxylic acid cyanomethyl esters optionally in the form of their racemates, enantiomers or diastereomers and optionally in the form of their salts and derivatives, their solvates and / or hydrates. Any reference to steroids includes reference to their optional salts or derivatives, hydrates or solvates. Examples of possible salts and derivatives of steroids may be: alkali metal salts, such as sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates. Preferred PDE4 inhibitors are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofylline, atizoram, D-4418, bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V- 11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and

N- (3,5-dichloro-1-oxo-pyridin-4-yl) -4-difluoromethoxy-3-cyclopropylmethoxybenzamide

- (-) p - [(4aR *, 10oS *) - 9-ethoxy-1,2,3,4,4a, 10b-hexahydro-8-methoxy-2-methylbenzo [s] [l, 6] naphthyridine 6-yl] -N, N-diisopropylbenzamide

(R) - (+) - 1- (4-bromobenzyl) -4 - [(3-cyclopentyloxy) -4-methoxyphenyl] -2-pyrrolidone 3- (cyclopentyloxy-4-methoxyphenyl) -1 - (4-N ' [N-2-cyano-S-methylisothioureido] benzyl) -2-pyrrolidone cis [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid] - 2-carbomethoxy-4- cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexane-1-one cis [4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexane-1-ol] (R) - (+) Ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate (S) - (-) - Ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate - 9-Cyclopentyl-5,6-dihydro-7-ethyl-3- (2-thienyl) -9H-pyrazolo [3,4-c] -1,4,4-triazolo [4,3-a] pyridine

9-cyclopentyl-5,6-dihydro-7-ethyl-3- (tert -butyl) -9H-pyrazolo [3,4-c] -1,4,4-triazolo [4,3-a] pyridine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, the acid addition salts of the PDE4 inhibitors are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,

Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafhiukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and - l - (((R) - (3- (2- (6,7-Difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio) methylcyclopropane -acetic acid,

- l - (((l (R) -3 (3- (2- (2,3-dichlorothieno [3,2-b] pyridin-5-yl) - (E) -ethenyl) phenyl) -3- ( 2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropaneacetic acid - [2 - [[2- (4-tert-butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl] phenyl] acetic acid optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. Examples of salts or derivatives which the LTD4-antagonists are capable of forming include: alkali metal salts, such as, for example, sodium or potassium salts, alkaline earth salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.

The EGFR inhibitors used are preferably compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and - 4 - [(3-chloro-4-fluorophenyl) amino] -6- {[4- (morpholin-4-yl) -1-oxo-2-butene-1-yl] amino} -7-cyclopropylmethoxyquinazoline

- 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-diethylamino) -l-oxo-2-buten-1-yl] -amino} -7-cyclopropylmethoxy quinazoline 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy quinazoline

4 - [(R) - (1-phenylethyl) amino] -6- {[4- (morpholin-4-yl) -1-oxo-2-butene-1-yl] amino} -7-cyclopentyloxy quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -l-oxo-2-butene - 1 -yl] -amino} -7-cyclopropylmethoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6 - {[4 - ((R) -6-methyl-2-oxo] morpholin-4-yl) -1-oxo-2-buten-1-ylamino} -7 - [(S) - (tetrahydrofuran-3-yl) oxy] quinazoline 4 - [(3-chloro-4-fluoro phenyl) amino] -6 - {[4 - ((R) -2-methoxymethyl-6-oxomorpholin-4-yl) -1-oxo-2-but-1-yl-amino} -7-cyclopropylmethoxy-quinazoline 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7-methoxy-quinazoline 4 - [(3-Chloro-4-fluorophenyl) amino] -6 - ({4- [N- (2-methoxyethyl) -N-methyl-amino] -l-oxo-2-butene-1-yl } amino) -7-cyclopropylmethoxyquinazoline 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -V-cyclopentyloxy-quinazoline - 4 - [(R) - (1-phenyl-ethyl) -amino] -6 - {[4- (N, N-bis (2-methoxy-ethyl) -amino] - 1-oxo-2-butene-1-yl-amino} -7-cyclopropylmethoxy-quinazoline

- 4 - [(R) - (1-Phenyl-ethyl) -amino] -6 - ({4- [N- (2-methoxyethyl) -N-ethyl-amino] -l-oxo-2-butene 1 -yl} amino) -7-cyclopropylmethoxy-quinazoline

- 4 - [(R) - (1-Phenyl-ethyl) -amino] -6 - ({4- [N- (2-methoxyethyl) -N-methyl-amino] -l-oxo-2-butene 1 -yl} amino) -7-cyclopropylmethoxy-quinazoline

4- [(R) - (1-phenylethyl) amino] -6- ({4- [N- (tetrahydropyran-4-yl) -N-methyl-amino] -1-oxo-2-butene-1 -yl} amino) -7-cyclopropylmethoxy-quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7 - ((R) tetrahydrofuran-3-oxy) quinazoline - 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -l-oxo-2-buten-1-yl ] amino} -7 - ((S) -tetrahydrofuran-3-oxy) -quinazoline

4 - [(3-Chloro-4-fluorophenyl) amino] -6 - ({4- [N- (2-methoxyethyl) -N-methyl-amino] -l-oxo-2-butene-1-yl } amino) -7-cyclopentyloxy-quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N-cyclopropyl-N-methyl-amino) -l-oxo-2-buten-1-yl] -amino} -7- cyclopentyloxy-quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -l-oxo-2-buten-1-yl] amino} -7- [(R) - (tetrahydrofuran-2-yl) methoxy] quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -l-oxo-2-buten-1-yl] amino} -7- [(S) - (tetrahydrofuran-2-yl) methoxy] quinazoline - 4 - [(3-ethynylphenyl) amino] -6,7-bis (2-methoxyethoxy) quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -7- [3- (morpholin-4-yl) -propyloxy] -6 - [(vinylcarbonyl) amino] quinazoline

4 - [(R) - (1-Phenyl-ethyl) -amino] -6- (4-hydroxy-phenyl) -7H-pyrrolo [2,3-d] pyrimidine

3-cyano-4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -l-oxo-2-buten-1-yl] amino} -7- ethoxy-quinoline

4 - {[3-Chloro-4- (3-fluoro-benzyloxy) -phenyl] -amino} -6- (5 - {[(2-methanesulfonyl-ethyl) -amino] -methyl} -furan-2-yl) -quinazoline

- 4 - [(R) - (1-phenylethyl) amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl] -l-oxo-2-one butene-1-yl] amino} -7-methoxy-quinazoline 4 - [(3-chloro-4-fluorophenyl) amino] -6- {[4- (morpholin-4-yl) -1-oxo-2-buten-1-ylamino] -

7- [(tetrahydrofuran-2-yl) methoxy] quinazoline

4 - [(3-Chloro-4-fluorophenyl) amino] -6- ({4- [N, N-bis (2-methoxy-ethyl) -amino] -1-oxo-2-butene-1-yl } amino) -7 - [(tetrahydrofuran-2-yl) methoxy] quinazoline - 4 - [(3-ethynylphenyl) amino] -6 - {[4- (5,5-dimethyl-2-oxomorpholine -4-yl) -1-oxo-2-butene-1-yl-amino} quinazoline

4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -

7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (2,2-dimethyl-6-oxomorpholin-4-yl) -ethoxy] - 7- [(R) - (tetrahydrofuran-2-yl) methoxy] quinazoline

4 - [(3-chloro-4-fluoro-phenyl) amino] -7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -

6 - [(S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {2- [4- (2-oxo-morpholin-4-yl) -piperidin-1-yl] -ethoxy} -7-methoxy quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [1- (tert-butyloxycarbonyl) -piperidin-4-yloxy] -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-amino-cyclohexan-1-ylxy) -7-methoxy-quinazoline

4- [(3-Chloro-4-fluorophenyl) amino] -6- (trans-4-methanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline

4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- (tetrahydropyran-3-oxy) -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(morpholin-4-yl) -carbonyl] -piperidin-4-yl-oxy} -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(methoxymethyl) -carbonyl] -piperidin-4-yl-oxy} -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (piperidin-3-yloxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [1- (2-acetylamino-ethyl) -piperidin-4-yloxy] -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7-ethoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6 - ((S) -tetrahydrofuran-3-yloxy) -7-hydroxyquinazoline

4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline 4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- {trans-4 - [(dimethylamino) sulfonylamino] -cyclohexane-1-yloxy} -7-methoxy-quinazoline

4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- {trans-4 - [(morpholin-4-yl) carbonylamino] -cyclohexane-1-yloxy} -7-methoxy-quinazoline-4- [(3-chloro-4-fluoro-phenyl) -amino] -6- {trans-4 - [(morpholin-4-yl) sulfonylamino] -cyclohexane-1-yloxy} -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (tetrahydropyran-4-yloxy) -7- (2-acetylamino-ethoxy) -quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methanesulfonylamino-ethoxy) -quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(piperidine-1-yl) -carbonyl] -piperidin-4-yloxy} -

7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-aminocarbonylmethyl-piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl ) amino] -6- (cis-4- {N - [(tetrahydropyran-4-yl) carbonyl] -N-methyl-amino} -cyclohexan-1-ylxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (cis-4- {N - [(morpholin-4-yl) -carbonyl] -N-methyl-amino} -cyclohexane-1-yloxy ) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluorophenyl) amino] -6- (cis-4- {N - [(morpholin-4-yl) sulfonyl] -N-methylamino} -cyclohexanilyloxy ) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-ethanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-ethoxy-quinazolin-4 - [(3-chloro-4-fluoro-phenyl ) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7- (2-methoxyethoxy) -quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (cis-4-acetylamino-cyclohexane-1-ylxy) -7-methoxy-quinazoline

4 - [(3-ethynyl-phenyl) -amino] -6- [1- (tert-butyloxycarbonyl) -piperidin-4-yloxy] -7-methoxy-quinazoline

4- [(3-ethynylphenyl) amino] -6- (tetrahydropyran-4-yloxy] -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (cis-4- {N - [(piperidine-1-yl) carbonyl] -N-methyl-amino} -cyclohexane-1-yloxy ) -7-methoxy-quinazoline 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (cis-4- {N - [(4-methylpiperazin-1-yl) carbonyl] -N-methyl-amino} -cyclohexane - 1-oxy) -7-methoxy-quinazoline

4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- {cis-4- [(morpholin-4-yl) carbonylamino] -cyclohexane-1-yloxy} -7-methoxy-quinazoline-4- [(3-chloro-4-fluoro-phenyl) -amino] -6- {1- [2- (2-oxopyrrolidin-1-yl) -ethyl] -piperidin-4-yloxy} -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(morpholin-4-yl) -carbonyl] -piperidin-4-yloxy} -7- (2-methoxyethoxy) - quinazoline

4- [(3-ethynylphenyl) amino] -6- (1-acetyl-piperidin-4-yloxy) -7-methoxy-quinazolin-4 - [(3-ethynyl-phenyl) -amino] -6- (1 methyl-piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-Ethynyl-phenyl) -amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-methyl-piperidin-4-yloxy) -7 (2-methoxy-ethoxy) -quinazoline-4 - [(3-chloro-4-yl) 4-fluoro-phenyl) amino] -6- (1-isopropyloxycarbonyl-piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (cis-4-methylamino-cyclohexane-1-yloxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {cis-4- [N- (2-methoxy-acetyl) -N-methyl-amino] -cyclohexane-1-yloxy} -7 methoxy-quinazoline

4 - [(3-ethynyl-phenyl) amino] -6- (piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-Ethynylphenyl) amino] -6- [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7-methoxy-quinazoline

4 - [(3-ethynylphenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(cis-2,6-dimethyl-morpholin-4-yl) -carbonyl] -piperidin-4-yloxy} -7- methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(2-methyl-morpholin-4-yl) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(S, S) - (2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(N-methyl-N-2-methoxyethyl-amino) -carbonyl] -piperidin-4-yloxy} -7-methoxy quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (1-ethyl-piperidin-4-yloxy) -7-methoxy-quinazoline 4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(2-methoxyethyl) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(3-methoxy-propyl-amino) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4- [ (3-Chloro-4-fluoro-phenyl) -amino] -6- [cis-4- (N-methanesulfonyl-N-methyl-amino) -cyclohexane-1-yloxy] -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- [cis-4- (N-acetyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-methylamino-cyclohexane-1-yloxy) -7-methoxy-quinazoline

4- [(3-Chloro-4-fluoro-phenyl) -amino] -6- [trans-4- (N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-oxy] -7-methoxy-quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (trans-4-dimethylamino-cyclohexane-1-ylxy) -7-methoxy-quinazolin-4 - [(3-chloro-4-fluoro -phenyl) -amino] -6- (trans-4- {N - [(morpholin-4-yl) carbonyl] -N-methyl-amino} -cyclohexan-1-ylxy) -7-methoxy-quinazoline

7 - [(S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline

4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline

4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-cyano-piperidin-4-yloxy) -7-methoxy-quinazoline, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and viozan, optionally in the form of their racemates, enantiomers , Diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, these acid addition salts are preferred selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

As Hl antihistamines here preferably compounds are used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, Cexchlorpheniramin, pheniramine, doxylamine, chlorphenoxamine , Dimenhydrinat, Diphenhy dramin, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates. According to the invention, these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

As pharmaceutically active substances, substance formulations or substance mixtures, all inhalable compounds are used, such as e.g. also inhalable macromolecules, as disclosed in EP 1 003 478. Preferably, substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.

Furthermore, the compound may be derived from the group of derivatives of ergot alkaloids, the triptans, the CGRP inhibitors, the phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.

As derivatives of ergot alkaloids: dihydroergotamine, ergotamine.

In general, the proportion of the corresponding matrix former in the powders according to the invention is more than 20% (w / w), particularly preferably more than 30% (w / w) of the dry mass of the powder. In a further preferred embodiment of the invention, the proportion of the corresponding matrix former, for example the polyol or Mannitolanteil more than 20% (w / w) of the dry mass of the powder, preferably between 30-80% (w / w), more preferably between 30-70% (w / w). According to these embodiments, the proportion of the corresponding matrix former can therefore be approximately 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% (w / w) of the dry mass of the powder. The corresponding embodiments apply in particular to powders in which polyols, in particular in which mannitol is used as matrix former.

In a further preferred embodiment, the powder according to the invention comprises matrix formers in a concentration such that the ratio of active ingredient: matrix former is 1: 999 to 1: 1, more preferably from 1:99 to 1: 2 (data: w / w). For the purposes of this information, the term "active substance" also means a combination of active substances.

If the powders according to the invention contain anticholinergics, preferably in combination with betamimetics and steroids, then the proportion of the active ingredient or the sum of the active ingredients is normally between 0.1 and 50% (w / w), preferably between 0.2 and 40% (w / w). w), also preferably between 0.2 to 30% (w / w) and between 0.2 to 20% (w / w) of the total weight of the powder.

In a further preferred form, the inhalable powders according to the invention contain a pharmaceutical active ingredient from the group of the EGFR antagonists. Inventive inhalable powders with an active ingredient from this active ingredient group have an active ingredient content of between 10 and 80% (w / w), preferably between 20 and 80% (w / w), more preferably between 30 and 80% (w / w) on Total weight of the powder can be.

Further preferred is an embodiment in which exclusively mannitol is used as matrix former.

The invention comprises corresponding production methods for producing inhalable powders according to the invention. Such powders can be mixed both directly as powder inhalants (multidose systems, pre-metered multi-dose systems and single-dose systems) and as components which are mixed with other (eg coarse-grained) auxiliary substances. use.

In the context of the present invention, it has surprisingly been found that an efficient after-drying of spray-dried powders which, as matrix formers, is particularly preferred for sugars, amino acids or polyols, preferably mannitol and leucine

Mannitol, contain, are particularly stable on storage, especially at temperatures greater than 20 ⁰ C, and are characterized by a high dispersibility, said drying takes place in the spray chamber by supplying a second drying gas. By supplying the second drying gas thus takes place a second drying step, which within the spray drying process before the

Particle separation takes place. The energy input of the second drying step is preferably to be selected such that the starting temperature is in the range of 40 ⁰ C to 100 ⁰ C.

Production processes according to the invention comprise the following steps:

(a) dissolving one or more active substances and the matrix-forming agent in water, an organic solvent or an organic-aqueous solvent mixture to produce a solution having a solids content between 1% by weight and 20% by weight, preferably between 2% by weight and 10% by weight, more preferably between 3% by weight and 8% by weight,

(B) spraying the solution thus obtained in a conventional manner, so that a spray with a drop size with

(i) the characteristic value Q ₍ 5.8 ₎ between 50% and 100% and (ii) the average droplet size X50 in the range from 1 μm to 20 μm, preferably from 1 μm to 8 μm, particularly preferably from 1 μm to 3 μm , is achieved

(c) drying the spray thus obtained by means of a drying gas using the following parameters:

(I) an inlet temperature of the drying gas (1) of 8O ⁰ C to 200 ⁰ C, preferably from 8O ⁰ C to 150 ⁰ C, more preferably from 90 ⁰ C to 160 ⁰ C, more preferably from 90 ⁰ C to 140 ⁰ C. more preferably from 100 ⁰ C to 150 ⁰ C and particularly preferably from 100 ⁰ C to 130 ⁰ C. (ii) after-drying of the aerosol in the spray chamber by a second drying gas (2), the temperature of the drying gas (2) being between 200 ^° C. and 400 ^° C.,

(iii) the ratio of the volume flow of drying gas (1): drying gas (2) is between 20: 1 and 3: 1,

(iv) the drying gas coefficient Vl is between 100 K and 2000 K and the drying coefficient Vl is between 250 K and 4000 K and

(V) a starting temperature of the drying gas of 40 ⁰ C to 90 ⁰ C and

(D) separating the dried solid particles from the drying gas stream in a conventional manner.

It has proven to be suitable to dissolve the active ingredient or a combination of active ingredients with one or more excipients, preferably with a polyol, more preferably with mannitol in water, an organic solvent or an organic-aqueous solvent mixture. As solvents according to the invention in addition to water organic solvents having a boiling point between 40 ⁰ C and 130 ⁰ C, preferably alcohols used. Preference is given to organic solvents which are either pharmaceutically acceptable or can be removed from the pharmaceutical formulation to a sufficient extent (if necessary, approval-relevant measure). Ethanol, methanol, propanol, dichloromethane, water or a mixture of these solvents are particularly preferably used according to the invention. The solids concentration of the spray solution serve to make the process economical. However, the drug concentration to be set limits are set, which are given by the fact that the surface properties of the particles including the particle size can be optimized by a certain ratio between drop size and solids concentration. Usually, a concentration between 1 wt .-% and 20 wt .-%, in a preferred manner between 2 wt .-% and 10 wt .-%, in a very preferred manner between 3 wt .-% and 8 wt .-% to choose. The drop size to be chosen during the process can be determined by the

Parameter X ₅₀ , which is in the range of 1 .mu.m to 20 .mu.m, preferably from 1 .mu.m to 8 .mu.m and particularly preferably from 1 .mu.m to 3 .mu.m, and the characteristic value Q (5.8), which is between 30% and 100% and preferred between 60% and 100%. In this case, the parameter X50 for the droplet size, the mean, volume-related droplet size is. The characteristic value Q denotes ₍₅ .8), the amount of particles of Droplet, which is based on the volume distribution of the droplets below 5.8 microns. The droplet sizes were determined in the context of the present invention by means of laser diffraction (Fraunhoferbeugung). More detailed information can be found in the experimental descriptions of the invention.

This is technically implemented in the context of spray drying, in which a corresponding commercial nozzle, z. B. two-fluid nozzle, which has these characteristics in dependence of the applied atomization pressure and the resulting mass flow of the atomizing gas and the spray rate (volume flow "spray solution") has. In addition to the special conditions that must be met in the actual spraying process in order to generate suitable droplets for the drying process, it can be seen that the properties of the particles can be positively / selectively influenced by the choice of the drying parameters.

Inventive method is characterized in that the spray mist is exposed to a drying process by introducing at least two drying gas streams. It proves to be advantageous if the drying gas stream (1) in the immediate vicinity of the generation of the spray in a rectified manner is introduced into the spray chamber. In contrast, the inflow of the second drying gas takes place as a supplementary drying of the aerosol before the

Particle separation by inflow of a drying gas (2) in the counterflow direction inside the spray chamber. This post-drying step is also characterized in that the final drying of the spray-dried particles takes place in such a way that the particles are present in aerosolized form, preferably in the spray chamber. The aerosol obtained by such a process, consisting of dried particles, which are present in the dispersed state in the volume flow of the drying gas is discharged from the spray chamber (see Figure 1: outlet of the spray chamber, marked with numeral 4). The separation of the dried solid particles from the drying gas flow takes place in the usual manner. This can be done for example by separation by means of a cyclone.

Parameters that are included in the drying step are the inlet temperature and mass flow of the drying gas (1) and the drying gas (2) and the mass flow of the spray liquid (Ml) and the starting temperature of the drying gas. The ratio of the mass flow of the respective drying gas (MgI, MgT) and the mass flow of the spray liquid (Ml) in conjunction with the temperature difference (ATl, ATT) between the respective drying gas (Tl, TT) and the outlet temperature (Ta) an important role.

The inlet temperature Tl of the drying gas (1) - the drying gas (1) is characterized by numeral 1 in Fig. 1 - here represents the temperature, which has the drying gas when introduced into the spray cylinder (measuring point see paragraph 7, Fig. 1). The mass flow of the drying gas Mg represents the amount of gas determined as mass per unit time, wherein MgI indicates the mass flow of the drying gas (1) and MgI the mass flow of the drying gas (2). The starting temperature (Ta) of the drying gas can be determined according to FIG. 1 at the measuring point 6 (number 6, FIG. 1). The inlet temperature Tl of the drying gas (2) - the drying gas (2) is characterized by numeral 2 in Fig. 1 - here represents the temperature of the drying gas (2), which can be measured before introducing the drying gas into the spray cylinder (see paragraph 5 , Fig. 1). Under the mass flow of

Spray liquid (Ml) (see paragraph 3, Fig. 1) is the amount (determined as mass) of spray solution per unit time. The temperature differences AT1 and AT1 respectively represent the temperature differences between the measuring points of the inventive process marked according to FIG. 1. According to the invention, the method for providing the inhalable powders according to the invention can be characterized by the drying coefficient V1 and the drying coefficient V1. The parameters Vl and Vl are accessible according to the mathematical relations equation 1 and equation 2.

Vl = • Δπ with ATl = Tl - Ta Equation 1

V2 = MiI. _AT2 with ATl = Tl - Ta Equation 2

ml

The method for providing the inhalable powders according to the invention is characterized in that the inlet temperature of the drying gas (1) between 80 ⁰ C to 150 ⁰ C, preferably from 90 ⁰ C to 140 ⁰ C and particularly preferably from 100 ⁰ C to 130 ⁰ C and the inlet temperature of the drying gas (2) is between 200 ⁰ C and 400 ⁰ C. Furthermore, the drying of the spray is carried out such that the drying coefficient Vl (see equation 1) has a value between 100 K to 2000 K, preferably between 200 K to 1500 K and more preferably between 400 K to 1000 K and the drying coefficient Vl (see equation 2) has a value between 250 K to 4000 K, preferably between 500 K to 3000 K and more preferably between 1000 K to 2000 K.

In a preferred manner, the process step of drying is characterized in that the ratio of the mass flow MgI: mass flow MgI is between 20: 1 and 3: 1.

The production method is also characterized in that the starting temperature of the drying gas, measured at the outlet of the spray chamber has a temperature of 40 ⁰ C to 90 ⁰ C, preferably 40 ⁰ C to 90 ⁰ C.

The manufacturing apparatus shown in Fig. 1 represents an embodiment by means of which the inventive method can be performed. The drawing

(Figure 1) shows a modified Büchi B-191 spray dryer with post-drying zone.

According to FIG. 1, the spray solution (3) is sprayed in the spray chamber, for example with the aid of a commercial two-fluid nozzle. The drying gas (1) is heated and introduced into the spray chamber in cocurrent to the spray. With the number (7), the measuring point of the inlet temperature of the spray gas (1) is marked. The drying gas (2) is heated and introduced in countercurrent to the spray cylinder. With the number (5), the measuring point of the inlet temperature of the drying gas (2) is marked. Labeling No. (6) represents the measurement point for the exit temperature of the drying gas, where (4) represents the outlet for the dried aerosol / drying gas.

The method according to the invention thus makes it possible to provide inhalation powders, the particles containing a crystalline matrix former, preferably mannitol. Particles according to the invention may contain active substances, the active substance or agents being incorporated into the crystalline adjuvant component, so that the active substance (s) are physically and chemically stabilized by this "scaffold formation." In a specific embodiment, it is surprisingly found that physically stable microparticles are present can be prepared, which allow a high proportion of active ingredient. Characterized are powder thus produced by a particle size, for example as measured by laser diffraction, by an average particle size X50 in the range of 1 .mu.m to 10 .mu.m, preferably from 1 .mu.m to 6 .mu.m. The term "average particle size" as used herein refers to the 50% value from the volume distribution measured by a laser diffractometer according to the dry dispersion method.

According to the invention, pharmaceutical preparations are also included, these being characterized by predosing the inhalable powders into a dose container. The dose containers may preferably be made of a material which, at least at the contact surface with the inhalable powder, has a material which is selected from the group of synthetic plastics.

Filled capsules containing the inhalable powders according to the invention may be mentioned as a preferred pre-dosed pharmaceutical preparation. The filling thereof is carried out according to methods known in the art of empty capsules with the inhalable powders according to the invention. For this purpose, those capsules are preferably used whose material is selected from the group of synthetic plastics, more preferably selected from the group consisting of polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate. Polyethylene, polycarbonate or polyethylene terephthalate are particularly preferred synthetic synthetic materials. If polyethylene is used as one of the capsule materials which are particularly preferred according to the invention, preference is given to polyethylene having a density between 900 and 1000 kg / m, preferably 940-980 kg / m, particularly preferably about 960-970 kg / m ³ (high-density polyethylene ) for use. The synthetic plastics in the context of the invention can be processed in many ways by means of the manufacturing process known in the art. Preferred in the context of the invention is the injection molding processing of plastics. Particularly preferred is the injection molding technique waiving the use of mold release agents. This production process is well defined and characterized by a particularly good reproducibility. According to the invention, the capsules are treated as powder reservoirs into which the pharmaceutical preparations according to the invention are filled in a product-contacting manner. This is understood to mean that powder reservoirs according to the invention are designed such that at least the material which contacts the pharmaceutical preparation is selected from a material from the group of synthetic plastics. Another aspect of the present invention relates to the aforementioned capsules containing the above-mentioned inhalable powder of the invention. These capsules may contain about 1 to 25 mg, preferably about 2 to 25 mg, more preferably about 3 to 20 mg of inhalable powder. According to these embodiments, the capsules 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 , 23, 24 or 25 mg inhalation powder.

The present invention further relates to an inhalation kit consisting of one or more of the capsules described above containing a content of inhalable powder according to the invention in combination with a dry powder inhaler.

The present invention further relates to the use of the inhalable powders according to the invention for the preparation of a medicament for the treatment of

Respiratory diseases, in particular for the treatment of COPD and / or asthma, characterized in that the inhaler disclosed in WO2004047796 (see FIG. 1 there) is used.

Examples

Example 1 (drying with additional drying gas (2)): Production of inhalation powder by means of spray drying to provide embedding particles. The particles thus obtained contain a combination of active ingredients (glucocorticoid, anticholinergic and beta-agonists) in a crystalline mannitol matrix.

Execution:

In an Erlenmeyer flask, the solvent (H ₂ OiEtOH 1: 0.9 m / m) is presented. The addition of the embedding material (mannitol) is carried out in portions with vigorous stirring (magnetic stirrer) and with heating (40 ⁰ C) in an ultrasonic bath. Once the solution is clear, the addition of the active ingredients takes place. After complete dissolution immediately follows the spray drying. The composition of the solution is shown in Table 1 below. Table 1: Solution Composition Example 1.

Here, beta-agonist CL provides the substance 2H-l, 4-benzoxazin-3 (4H) -one, 6-hydroxy-8- [(1R) -1-hydroxy-2- [[2- (4-methoxyphenyl) - 1, 1 -dimethylethyl] ethyl] -, monohydrochloride and tiotropium BR the substance tiotropium bromide, as it is known from the European patent application EP 418 716 Al, is.

Spray drying is carried out with a BÜCHI Mini-Spray Dryer (B-191) in combination with a two-substance nozzle (Büchi, 0.5 mm, item 4363). The spray dryer was modified to remove the aspirator. About the process gas inlet N ₂ is supplied as drying gas (about 17 m ³ / h with about 90 ⁰ C), so that the device is flowed through in the overpressure range (corresponds to drying gas (I)). As a second drying stage, ambient air is sucked in and fed to the process (about 3 m ³ / h with about 400 ⁰ C) (corresponds to drying gas (2)). The output filter between cyclone and aspirator has been removed and the gas outlet directly drained. The mass flow of the

Nozzle gas flow rate is determined by an external measuring device (Kobold DSM212) and decoupled from the original variable area flowmeter. The nozzle is operated at a gas flow rate of 18 l / min (about 2 bar overpressure). The solvent throughput is about 16 g / min. The resulting outlet temperature is in the range of approx. 58 ° C. The process parameters used are listed in Table 2.

Table 2: Spray drying parameters Example 1 {Drying with additional drying gas (2)).

The composition of the powder obtained according to Example 1 is shown in Table 3.

Table 3: Composition of solid particles (calculated) Example 1 (drying with additional drying gas (2J).

Characterization of the obtained particles / of the inhalation powder:

Characteristic properties of the inhalable powders obtained according to Example 2 are in

Table 4 listed. The geometric mean particle size (laser diffraction:

Sympatec dry dispersing) directly after preparation.

In addition, the inhalable particles were detected as "volume fraction <5μm

This is understood to mean the amount of powder whose particles are smaller than 5 μm (stated in% by volume), measured by means of laser diffraction.

In this case, the generation of the aerosol cloud by a deagglomeration of the sample by means of application of an inhaler (Handihaler) - for more details see section

Methods section.

It can be seen that the "volume fraction <5 microns after application" is stable the inhalable powders according to Example 1. The decrease in the "volume fraction <5 microns after application" after storage (1 week, open, 40 ⁰ C / 75% rh) is negligible. Negligible is a decrease of less than 5% points, preferably less than 4% points, more preferably less than 3% points and most preferably less than 2% points and most outstandingly less than 1% points after storage ( 1 week, open, 40 ^° C / 75% rh). In this case,% percentage points are to be understood as percentages based on 100% (volume percent).

Table 4: Powder properties Example 1 {Drying with additional drying gas

(2)).

measurement methods

I) Particle size determination by laser diffraction (Sympatec dry dispersion) to determine the average particle size X ₅₀ :

Meter and settings:

The operation of the equipment was carried out in accordance with the manufacturer's instructions.

Measuring instrument: Laser diffraction spectrometer (HELOS), Sympatec (particle size determination by means of fraunhof diffraction) Dispersion unit: Dry disperser RODOS with suction funnel, Sympatec

Sample amount: 200 mg ± 150 mg

Product feed: vibrating trough Vibri, Fa. Sympatec

Frequency d. Vibrating trough: up to 100% rising

Duration of sample feeding: 15 to 25 sec. (in the case of 200 mg)

Focal length: 100 mm (measuring range: 0.9 - 175 μm)

Measuring time / waiting time: approx. 15 s (in the case of 200 mg)

Cycle time: 20 ms

Start / Stop at: 1% on channel 28

Dispersing gas: compressed air

Pressure: 3 bar

Under pressure: maximum

Evaluation mode: HRLD

Sample preparation / product delivery:

Approximately 200 mg of the test substance are weighed on a map sheet.

With another map sheet, all larger agglomerates are crushed.

The powder is then placed on the front half of the vibrating trough (from about 1 cm from the front

Rand) scattered finely distributed.

After the start of the measurement, the frequency of the vibrating trough is varied so that the

Feed the sample as continuously as possible. The amount of product must not be too large so that adequate dispersion is achieved. II) Determination of the "volume fraction <5 μm after application" as application from an inhaler (HandiHaler):

The inhaler HandiHaler® is used for the determination. The inhalable powder to be analyzed is filled into capsule size 3 plastic capsules (polyethylene) as disclosed in EP 1100474. The inhalation capsules are filled with 20 mg.

Execution:

(The application to determine the "volume fraction <5μm after application" is carried out according to the technical structure see Fig. 2.)

The HandiHaler® is operated with compressed air (8) via a gas connection at the inlet opening of the capsule chamber. The applied flow rates are 39 l / min and 60 l / min (preferably 39 l / min, as this corresponds to a pressure drop on the HandiHaler® of 4 kPa). With the aid of a time-controlled 2-way solenoid valve (9) compressed air is supplied to the inhaler (12) over a period of 10 seconds. The flow rate adjustment is made via a flow control valve (10) and flow rate control via a Kobold DMS-614C3FD23L mass flow meter (11). The particle size distribution is determined directly at the aerosol cloud by measuring the particle size at a distance of 2 ± 0.5 cm behind the powder outlet from the inhaler using the HELOS laser diffractometer Sympatec GmbH, Clausthal-Zellerfeld (13). Directly behind the measuring zone the particles are sucked off by a vacuum cleaner (14).

Measurement conditions: The focal length of the laser diffractometry is f = 100 mm (measuring range: 0.9 - 175 μm). The evaluation is done in high-resolution mode (Fraunhofer HRLD, software version WINDOX 4.1.2.0) assuming the spherical model (form factor = 1).

Evaluation: The target volume "volume fraction <5μm after application" corresponds to the volume fraction of the particles in percent, which are smaller than 5 μm. III) Determination of crystallinity

Meter and Settings: Meter: Temperature Modulated DSC (TMDSC)

Q1000 TA Instruments

Sample crucible: standard crucible, perforated

Sample amount: 10 mg ± 2 mg

Modulation: ± 0.54 ° C, period 40 seconds

Heating rate: 5 ° C / min

Temperature range: -40 ⁰ C to 200 ⁰ C

Evaluation:

Software: TA Instruments Universal 2000 (Version 4.2)

RevCP signal: Smooth = 4; Step analysis Tg

1. Tg [ ⁰ C]: Center point of the Cp stage from the RevCp signal

2. ΔCp [J / (g- ° C)]: increase in heat capacity at the glass transition from the RevCp signal

The glass step is determined by means of the TA Instruments software (Universal 2000, Version 4.2) from the RevCP signal via the function "Analyze / Glass Transition ..." The limit points are hereby set to the baseline before and after the glass step, eg at McPhillips et al., [McPhillips, H., Craig, DQM; Royall, PG; Hill, L .: Characterization of the glass transition of HPMC using modulated temperature differential scanning calorimetry; International Journal of Pharmaceutics (1999) No. 180 , 83-90].

If the sample has amorphous parts, a Cp increase at the glass transition of the sample (ACp ₍ p ₎ ) can be observed. For such a sample, the degree of crystallinity can be calculated from the magnitudes Cp slope at the glass transition of the sample (ACp (p)), the Cp slope of the fully amorphous matrix former (ACp (M, a)) and the proportion of sample present in the sample Matrix former (A (M)) according to Equation 3,

ACp _{P) - 10000

Crystallinity [%] = 100 - (Equation 3)

ΔCp (M, a) ^' A (M) where

ACp (p) [J / (g- ° C)]: Cp increase at the glass transition of the sample ΔCp (M, _a ) [J / (g- ° C)]: Cp increase at the glass transition of the fully amorphous

Matrix former A (M) [%]: Mass fraction of the matrix former in the sample

represents.

Amorphous reference material for determining crystallinity:

For the determination of ACp (M.a) according to equation 3, the matrix former in amorphous

Form needed as reference material. The preparation of the amorphous reference substance is done for example by melting and sudden cooling (quenching) of the substance. For this purpose, 10 + 2 mg of the matrix former are weighed in a DSC crucible and heated in the TMDSC apparatus to about 10 to 30 ⁰ C above the melting temperature. The crucible is removed at this temperature and immediately immersed in cryogenic liquid nitrogen. The determination of the Cp increase ACp (Ma) takes place in which the sample of the completely amorphous matrix former is placed in the furnace of the TMDSC apparatus and measured after production. The measurement is started at least 20 ⁰ C below the expected glass transition point. The measurement is carried out according to the device parameters listed above (TA Instruments Software, Universal 2000, Version 4.2) via the function "Analyze / Glass Transition ...").

IV) Determination of drop size by laser diffraction

Measuring method: To determine the droplet size, the spray cone (spray) of

Nozzle analyzed directly in the laser measuring zone with respect to the drop size distribution. The median value X ₅₀ is the drop size below which 50% of the drop quantity lies. The characteristic value Q ₍₅ .8 ₎ value describes the percentage of drops that are below 5.8 μm in size. H ₂ O is used as solution. The characteristic value is designated as mean droplet size X50.

Measuring instrument: Laser diffraction spectrometer (HELOS) _{5 from} Sympatec

Software: WINDOX Version 4

Dispersing unit: RODOS / dispersing pressure: 3 bar

Focal length: 100 mm [measuring range: 0.9 175 μm] Evaluation mode: Mie (V 4)

Claims

claims

1.) A method for providing inhalable powder comprising a crystalline matrix former which is selected from a group consisting of sugars, polyols, polymers, amino acids, proteins, di-, tri-, oligo- and polypeptides; and one or more active pharmaceutical ingredients,

characterized in that a spray solution comprising the matrix former and the pharmaceutically active agent is spray dried, comprising the steps: (a) dissolving one or more active ingredients and the matrix former in water, an organic solvent or an organic-aqueous solvent mixture to prepare a solution with a dissolved solids content between 1 wt .-% and 20 wt .-%, preferably between 2 wt .-% and 10 wt .-%, particularly preferably between 3 wt .-% and 8 wt .-%, (b) spraying the solution thus obtained in a private way, so that a

Spray having a droplet size with (i) the characteristic value Q (. ₅ ₈₎ between 50% and 100%, and (ii) the average droplet size X50 in the range from 1 .mu.m to 20 .mu.m, preferably from 1 micron to 8 microns, more preferably from 1 μm to 3 μm, is achieved

(I) an inlet temperature of the drying gas (1) of 8O ⁰ C to 200 ⁰ C, preferably from 90 ⁰ C to 160 ⁰ C and particularly preferably from 100 ⁰ C to 150 ⁰ C and

(ii) drying the aerosol in the spray chamber through a second

Drying gas (2), wherein the temperature of the drying gas (2) is between 200 ⁰ C and 400 ⁰ C,

(iv) the drying gas coefficient Vl between 100 K and 2000 K and the

Drying coefficient V2 is between 250 K and 4000 K and (v) a starting temperature of the drying gas of 40 ⁰ C to 90 ⁰ C and

2.) The method of claim 1 for providing inhalable powder containing a crystalline matrix former, characterized in that the matrix former is selected from a polyol.

3.) The method of claim 2 for providing inhalable powder containing a crystalline matrix former, characterized in that the matrix former is mannitol.

4.) Method according to one of claims 1 to 3, characterized in that the active substance or substances preferably selected from the group consisting of anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, LTD4 antagonists, EGFR-kinase inhibitors, dopamine Agonists, HIV antihistamines, PAF antagonists, P13 kinase inhibitors, P38 MAP kinase inhibitors, antiallergic agents and phosphodiesterase V inhibitors.

5.) Method according to one of claims 1 to 4, characterized in that the temperature of the drying gas (2) is between 300 ⁰ C and 380 ⁰ C.

6.) Method according to one of claims 1 to 5, characterized in that the

Ratio of the volume flow of drying gas (1): Drying gas (2) is between 18: 1 and 10: 1 (mass ratios).

7.) Spray-dried powder obtainable by a process according to claim 1 to 6, characterized in that this mannitol contains as a matrix former and as an active ingredient an EGFR inhibitor, wherein the ratio of active ingredient: matrix former between 1: 1 to 3: 1 (mass ratios) ,

8.) Spray-dried powder obtainable by a process according to claim 1 to 6, characterized in that this mannitol as matrix former and as active ingredient a combination of an anticholinergic, betamimetics and steroids wherein the ratio of the sum of the active ingredients: matrix former between 1: 1 to 3 : 1 (mass ratios) lies Inhalation kit containing an inhalation device suitable for application of

Contentsion powders can be used from powder-containing capsules, and a spray-dried powder according to claims 7 to 8 contains.